Atrial Fibrillation

This channel includes news and new technology innovations for the treatment of atrial fibrillation, also referred to as AF or afib. AF is a cardiac arrhythmia caused by irregular and often rapid heart rate. It is caused by the upper chambers (the atria) beating irregularly and uncoordinated with the lower  ventricle chambers of of the heart. Symptoms include weakness with heart palpitations and shortness of breath. The conditional can lead to an increased risk of stroke and heart failure. AF episodes can cause the blood in the atria to stagnate and form clots, usually within the left atrial appendage (LAA). The clots can flow to the brain and cause a stroke. Treatments include anticoagulation therapy to dissolve clots, catheter or surgical ablation and LAA occlusion

First Results Reported from AVIATOR 2 Registry for AFib Patients Undergoing PCI.

Photo courtesy of the American Heart Association

News | Atrial Fibrillation | May 15, 2018

May 15, 2018 – Results of the AVIATOR 2 international registry data show a discrepancy between physician perception...

New Combined Risk Score More Effectively Predicts Stroke Risk in AFib Patients

Image courtesy of Intermountain Medical Center Heart Institute

News | Atrial Fibrillation | May 11, 2018

May 11, 2018 — A new ...

Online ECG Monitoring Detects Paroxysmal AFib More Effectively Than Holter, Patch Methods
News | ECG Monitoring Services | May 09, 2018

May 9, 2018 – Medicalgorithmics S.A. will present the results of a large...

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

 

Feature | Antiplatelet and Anticoagulation Therapies | May 07, 2018

May 7, 2018 — The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first...

The Abbott Advisor HD Grid Mapping Catheter, Sensor Enabled, allows high density electro mapping for transcatheter EP cardiac ablation procedures.
Technology | EP Mapping and Imaging Systems | May 03, 2018

May 3, 2018 — The U.S. Food and Drug Administration (FDA) has granted market clearance for the Abbott Advisor HD...

Medtronic Cryoballoon Shows Positive Results for Patients With Persistent Atrial Fibrillation
News | Ablation Systems | April 12, 2018

April 12, 2018 — Medtronic plc announced one-year results from the CRYO4PERSISTENT AF study of...

Depression Linked to Increased Atrial Fibrillation Risk
News | Atrial Fibrillation | March 27, 2018

March 27, 2018 — Depression may increase the risk for...

Self-Applied Chest Patch Catches Atrial Fibrillation More Quickly Than Usual Care
News | Wearable Sensors | March 19, 2018

March 19, 2018 — For people at heightened risk for...

ECG on Smartwatch Accurately Detects AFib
News | ACC | March 15, 2018

March 15, 2018 – A newly-designed wristband and corresponding app that works with a smartwatch can accurately...

ACC 2018 highlights and trends.  #acc.18, #ACC, #ACC2018
Feature | ACC | January 31, 2018

The rapid pace of change continues to be a hallmark in cardiovascular medicine and many see that pace accelerating....

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation.

Boston Scientific's Apama multi-electrode ablation balloon to treat atrial fibrillation. The technology allows different energies to be used for each electrode to prevent damage to the esophagus or other underlying critical structures. 

Feature | Atrial Fibrillation | January 15, 2018 | Dave Fornell

The development of atrial fibrillation (AFib or AF) ablation technologies over the past 20 years has been a constant...

Heart Rhythm Society Partners With WebMD Education to Increase Atrial Fibrillation Awareness
News | Atrial Fibrillation | January 02, 2018

January 2, 2018 — The Heart Rhythm Society (HRS), in partnership with WebMD Education, announced in December the...

The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time.

The Boston Scientific Rhythmia Mapping System produces higher-density voltage maps without increasing overall procedure time. It was the first of a new generation of high-density mapping systems to be introduced.

Feature | Atrial Fibrillation | December 18, 2017 | Kenneth Stein, M.D. FACC FHRS

When I began practicing as an electrophysiologist in 1994, the dream of successfully using cardiac catheter ablation...

New Oral Anticoagulant Drugs Associated with Lower Kidney Risks
News | Antiplatelet and Anticoagulation Therapies | December 12, 2017

December 12, 2017 — Mayo Clinic researchers have shown a link between which type of...

News | Antiplatelet and Anticoagulation Therapies | November 16, 2017

November 16, 2017 — Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes...

Overlay Init